Amgen, Teva to face Sensipar monopoly claims

Amgen and Teva will have to face a lawsuit accusing them of restricting competition by engineering a reverse payment designed to keep generic versions of Sensipar (cinacalcet) off the market.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Generics

Teva wins Fed Circ appeal over J&J’s schizophrenia drug

2 April 2024 Teva and co-appellant Mylan gain second chance at launching generics of Invega Sustenna, owned by J&J subsidiary Janssen | US Court of Appeals vacates a lower court’s decision to grant validity to the drug’s last remaining patent.

Generics

Bayer granted 10-day injunction in blood clot drug dispute

28 March 2024 Judge disagrees that barrier against generic drug makers should be longer | Pharma company argues that ‘window should be shut’ on copycat versions due to potential for irreparable harm.

Generics

‘March-in’ rights: Why Biden’s changes contradict the point of Bayh-Dole

18 February 2024 While President Biden’s desire to reduce costs at the pharmacy counter is commendable, it is too blunt an instrument that would threaten innovation beyond the life sciences, argue former USPTO directors Andrei Iancu and David Kappos.

More features

Mental health in IP: ‘We have a clear picture of the problem’

From Edwards to Insulet: Three key medical device cases of 2025

Edwards v Meril: Behind the UPC’s landmark medtech showdown

5 ways the USPTO director is changing US innovation

EU unveils sweeping pharma, biotech, and medical device reforms

Mirum targets generics in quartet of suits over liver treatment

Hogan Lovells and Cadwalader strike historic deal to create $3.6bn firm

Edwards v Meril: 3 insights from the UPC Court of Appeal’s decision

Amgen, Teva to face Sensipar monopoly claims

More on this story

Editor's picks

Editor's picks

More features